HRP20050176A2 - Novel processes for making - and a new crystalline form of-leflunomide - Google Patents

Novel processes for making - and a new crystalline form of-leflunomide

Info

Publication number
HRP20050176A2
HRP20050176A2 HR20050176A HRP20050176A HRP20050176A2 HR P20050176 A2 HRP20050176 A2 HR P20050176A2 HR 20050176 A HR20050176 A HR 20050176A HR P20050176 A HRP20050176 A HR P20050176A HR P20050176 A2 HRP20050176 A2 HR P20050176A2
Authority
HR
Croatia
Prior art keywords
leflunomide
making
crystalline form
new crystalline
novel processes
Prior art date
Application number
HR20050176A
Other languages
English (en)
Inventor
Aronhime Judith
Avrutov Ilya
Gershon Neomi
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HRP20050176A2 publication Critical patent/HRP20050176A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
HR20050176A 1999-12-16 2000-12-14 Novel processes for making - and a new crystalline form of-leflunomide HRP20050176A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17123799P 1999-12-16 1999-12-16
US17122899P 1999-12-16 1999-12-16
US18264700P 2000-02-15 2000-02-15
US20241600P 2000-05-08 2000-05-08
PCT/US2000/033866 WO2001043742A1 (en) 1999-12-16 2000-12-14 Novel processes for making- and a new crystalline form of- leflunomide

Publications (1)

Publication Number Publication Date
HRP20050176A2 true HRP20050176A2 (en) 2005-08-31

Family

ID=27496942

Family Applications (2)

Application Number Title Priority Date Filing Date
HR20050176A HRP20050176A2 (en) 1999-12-16 2000-12-14 Novel processes for making - and a new crystalline form of-leflunomide
HR20020521A HRP20020521A2 (en) 1999-12-16 2000-12-14 Novel processes for making - and a new crystalline form of - leflunomide

Family Applications After (1)

Application Number Title Priority Date Filing Date
HR20020521A HRP20020521A2 (en) 1999-12-16 2000-12-14 Novel processes for making - and a new crystalline form of - leflunomide

Country Status (15)

Country Link
US (3) US6610718B2 (enExample)
EP (1) EP1242077A4 (enExample)
JP (1) JP2003517011A (enExample)
KR (1) KR20020067545A (enExample)
CN (1) CN1411373A (enExample)
AU (1) AU779931B2 (enExample)
CA (1) CA2397601A1 (enExample)
CZ (1) CZ20022000A3 (enExample)
HR (2) HRP20050176A2 (enExample)
HU (1) HUP0204069A3 (enExample)
IL (1) IL149792A0 (enExample)
PL (1) PL356243A1 (enExample)
SK (1) SK8332002A3 (enExample)
WO (1) WO2001043742A1 (enExample)
YU (1) YU45102A (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT903345E (pt) * 1997-08-08 2001-01-31 Aventis Pharma Gmbh Forma cristalina de n-(4-trifluorometilfenil)-5-metil-isoxazolo-4-carboxamida
CZ20022000A3 (cs) * 1999-12-16 2003-02-12 Teva Pharmaceuticals Industries Ltd. Způsoby přípravy a nová krystalická forma leflunomidu
AU2001228454A1 (en) * 2000-01-13 2001-07-24 Merck Patent G.M.B.H Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary
HUP0301865A3 (en) * 2000-02-15 2005-12-28 Teva Pharma A method for synthesizing leflunomide
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
WO2006103506A1 (en) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Sertraline-containing pharmaceutical compositions and a process for preparation thereof
WO2008040149A1 (en) * 2006-09-05 2008-04-10 Dexian Dou Composition and method for treating immune-mediated skin disorders
CN101143834B (zh) * 2006-09-15 2010-09-08 欣凯医药化工中间体（上海）有限公司 N-(4-三氟甲基苯)-2-氰基-3-羟基丁烯酰胺钠盐的多晶型及其制备方法
US8664390B2 (en) 2007-06-29 2014-03-04 Generics (Uk) Limited Process for the introduction of hydroxyethoxy side chain in bosentan
AU2008315757A1 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
NZ587793A (en) 2008-02-08 2012-06-29 Generics Uk Ltd Process for preparing bosentan
CN102272108A (zh) 2008-11-03 2011-12-07 基因里克斯(英国)有限公司 用于分析波生坦及相关物质的hplc方法以及这些物质作为参比标准和标记的用途
CN101817797B (zh) * 2009-02-26 2013-04-10 江苏亚邦爱普森药业有限公司 高纯度3-甲基-n-[4-(三氟甲基)苯基]-4-异噁唑甲酰胺的合成方法
SG10202012791TA (en) 2013-11-15 2021-01-28 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
US11801232B2 (en) * 2019-11-27 2023-10-31 Yale University Targeting of ARID1A-deficient cancers by inhibiting de novo pyrimidine synthesis pathway
CN112898215B (zh) * 2021-02-04 2022-11-08 美罗药业股份有限公司 一种来氟米特晶型i的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
US5268382A (en) * 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
GB8619432D0 (en) * 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
DE59010701D1 (de) * 1990-05-18 1997-05-22 Hoechst Ag Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
DE19610955A1 (de) * 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
DE19711800A1 (de) * 1997-03-21 1998-09-24 Hoechst Ag Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung
PT903345E (pt) * 1997-08-08 2001-01-31 Aventis Pharma Gmbh Forma cristalina de n-(4-trifluorometilfenil)-5-metil-isoxazolo-4-carboxamida
EP0933633A1 (en) * 1997-12-11 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Process for obtaining L-dihydroorotic acid and use thereof
US7691890B2 (en) * 1998-03-11 2010-04-06 James W. Williams Anti-viral uses of leflunomide products
US6303652B1 (en) * 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6395763B1 (en) * 1999-06-25 2002-05-28 Vertex Pharmaceuticals Incorporated Prodrugs of carbamate inhibitors of IMPDH
CZ20022000A3 (cs) * 1999-12-16 2003-02-12 Teva Pharmaceuticals Industries Ltd. Způsoby přípravy a nová krystalická forma leflunomidu
HUP0301865A3 (en) * 2000-02-15 2005-12-28 Teva Pharma A method for synthesizing leflunomide
AU2001251011A1 (en) * 2000-03-27 2001-10-08 The General Hospital Corporation Treatments for immune-mediated ear disorders
AU2001284891A1 (en) * 2000-08-14 2002-02-25 Teva Pharmaceutical Industries Ltd. Micronized leflunomide
MXPA03001632A (es) * 2000-08-24 2004-09-10 Univ Tennessee Res Corp Moduladores receptores de androgeno selectivos y metodos para usar los mismos.
JP4212278B2 (ja) * 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
US20040229849A1 (en) * 2002-09-24 2004-11-18 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
EP1684820A2 (en) * 2003-08-13 2006-08-02 Medtronic, Inc. Active agent delivery systems including a miscible polymer blend, medical devices, and methods
WO2005018697A2 (en) * 2003-08-13 2005-03-03 Medtronic, Inc. Active agent delivery systems, including a single layer of a miscible polymer blend, medical devices, and methods
WO2005023201A2 (en) * 2003-09-09 2005-03-17 Medarex, Inc. Methods for treating rheumatoid arthritis

Also Published As

Publication number Publication date
JP2003517011A (ja) 2003-05-20
SK8332002A3 (en) 2003-04-01
HUP0204069A2 (hu) 2003-04-28
PL356243A1 (en) 2004-06-28
KR20020067545A (ko) 2002-08-22
US20050004191A1 (en) 2005-01-06
EP1242077A1 (en) 2002-09-25
CZ20022000A3 (cs) 2003-02-12
CN1411373A (zh) 2003-04-16
US20010031878A1 (en) 2001-10-18
US20030203952A1 (en) 2003-10-30
WO2001043742A1 (en) 2001-06-21
AU779931B2 (en) 2005-02-17
HUP0204069A3 (en) 2005-01-28
AU2578801A (en) 2001-06-25
IL149792A0 (en) 2002-11-10
EP1242077A4 (en) 2006-01-04
US6610718B2 (en) 2003-08-26
HRP20020521A2 (en) 2004-08-31
US6806373B2 (en) 2004-10-19
YU45102A (sh) 2006-01-16
CA2397601A1 (en) 2001-06-21

Similar Documents

Publication Publication Date Title
IL159332A0 (en) A knowledge-engineering protocol-suite
IL140079A0 (en) Process for producing bisphennol a
AU142007S (en) A cafetiere
HRP20050176A2 (en) Novel processes for making - and a new crystalline form of-leflunomide
PL352291A1 (en) Process for making a pipa-polyol
GB9919714D0 (en) A tool
SG99351A1 (en) Process for the manufacture of a crystalline solid
GB9901349D0 (en) A process
AU140192S (en) A tool
IL146972A0 (en) A substantially crystalline form of melagatran
EP1204445A4 (en) CRYSTALLIZATION MACHINE
ZA982925B (en) A new process for preparing a compound
GB0014546D0 (en) A novel process
GB9916754D0 (en) A composition
SG99292A1 (en) A method for producing oxide compounds
GB2346143B (en) A compound
GB2355450B (en) A carton for fixings
IL132519A0 (en) A food-serving holder
GB2349386B (en) A compound
GB9914111D0 (en) A tool
ZA200203967B (en) Novel processes for making- and a new crystalline form of leflunomide.
GB9906874D0 (en) A compound
SI1196431T1 (sl) V bistvu kristalna oblika melagatrana
AU138548S (en) A holder
AU143085S (en) A holder

Legal Events

Date Code Title Description
A1OB Publication of a patent application
OBST Application withdrawn